A PAR4 and FPR2 antagonist and an FFAR2 agonist
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

P4pal10 (trifluoroacetate salt)

Item No. 36913

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
N-(1-oxohexadecyl)-L-serylglycyl-L-arginyl-L-arginyl-L-tyrosylglycyl-L-histidyl-L-alanyl-L-leucyl-L-argininamide, trifluoroacetate salt
Synonyms
  • Palmitoyl-SGRRYGHALR-amide
  • Palmitoyl-SGRRYGHALR-NH2
Molecular Formula
C65H112N22O13 • XCF3COOH
Formula Weight
1409.7
Purity
≥98%
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
PBS (pH 7.2): 1 mg/ml
SMILES
OC(C=C1)=CC=C1C[C@@H](C(NCC(N[C@H](C(N[C@@H](C)C(N[C@@H](CC(C)C)C(N[C@H](C(N)=O)CCCNC(N)=N)=O)=O)=O)CC2=CN=CN2)=O)=O)NC([C@H](CCCNC(N)=N)NC([C@H](CCCNC(N)=N)NC(CNC([C@H](CO)NC(CCCCCCCCCCCCCCC)=O)=O)=O)=O)=O.OC(C(F)(F)F)=O
InChi Code
InChI=1S/C65H112N22O13.C2HF3O2/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-24-52(90)83-51(38-88)58(96)78-36-53(91)81-46(22-19-30-75-64(69)70)59(97)85-47(23-20-31-76-65(71)72)60(98)87-49(33-42-25-27-44(89)28-26-42)57(95)77-37-54(92)82-50(34-43-35-73-39-79-43)61(99)80-41(4)56(94)86-48(32-40(2)3)62(100)84-45(55(66)93)21-18-29-74-63(67)68;3-2(4,5)1(6)7/h25-28,35,39-41,45-51,88-89H,5-24,29-34,36-38H2,1-4H3,(H2,66,93)(H,73,79)(H,77,95)(H,78,96)(H,80,99)(H,81,91)(H,82,92)(H,83,90)(H,84,100)(H,85,97)(H,86,94)(H,87,98)(H4,67,68,74)(H4,69,70,75)(H4,71,72,76);(H,6,7)/t41-,45-,46-,47-,48-,49-,50-,51-;/m0./s1
InChi Key
OJIKJVREHBBQPJ-AIIGDNIWSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    5 mg

    $62

    Add

    10 mg

    $117

    Add

    25 mg

    $274

    Add

    50 mg

    $486

    Add
    Cayman Chemical
    Neutrophil Biology Wall Poster

    Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.

    DOWNLOAD NOW
    Product Description

    P4pal10 is a pepducin antagonist of proteinase-activated receptor 4 (PAR4) and formyl peptide receptor 2 (FPR2), as well as an agonist of free fatty acid receptor 2 (FFAR2/GPR43).1,2 It is composed of a peptide that corresponds to the third intracellular loop of human PAR4 that is conjugated to palmitic acid (Item No. 10006627).1 P4pal10 selectively inhibits the aggregation of isolated human platelets induced by the PAR4 peptide agonist AYPGKF-NH2 (Item No. 24258; IC50 = 0.5-1 µM) over the PAR1 peptide agonist SFLLRN-NH2 (Item No. 36881), the TP receptor agonist U-46619 (Item No. 16450), the platelet glycoprotein Ib (GPIb), GPIX, and GPV agonist ristocetin, ADP (Item No. 21121), or collagen at 5 µM. It inhibits increases in intracellular calcium induced by the FPR1 and FPR2 agonist WKYMVm but not by the FPR1 agonist fMLF in isolated human neutrophils and induces superoxide production in TNF-α primed isolated human neutrophils stimulated with the FFAR2 allosteric modulator Cmp58.2 P4pal10 (1, 3, or 10 µg/kg) reduces myocardial infarct size in a rat model of coronary artery ligation-induced ischemia-reperfusion injury.3 It increases the paw withdrawal threshold in rat models of osteoarthritis induced by monoiodoacetate injection into the knee joint or medial meniscal transection.4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Covic, L., Misra, M., Badar, J., et al. Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat. Med. 8(10), 1161-1165 (2002).

    2. Holdfeldt, A., Lind, S., Hesse, C., et al. The PAR4-derived pepducin P4Pal10 lacks effect on neutrophil GPCRs that couple to Gαq for signaling but distinctly modulates function of the Gαi-coupled FPR2 and FFAR2. Biochem Pharmacol. 114143, (2020).

    3. Strande, J.L., Hsu, A., Su, J., et al. Inhibiting protease-activated receptor 4 limits myocardial ischemia/reperfusion injury in rat hearts by unmasking adenosine signaling. J. Pharmacol. Exp. Ther. 324(3), 1045-1054 (2008).

    4. O'Brien, M.S., and McDougall, J.J. Targeting proteinase activated receptor-4 reduces mechanonociception during the acute inflammatory phase but not the chronic neuropathic phase of osteoarthritis in rats. Front. Pharmacol. 12, 756632 (2021).